Key result
Non-peptidic direct renin inhibitors have shown increasing structural diversity in patents from 2000-2008, with several novel small-molecule candidates advancing to Phase II clinical trials.
This review highlights the structural diversity and development of novel non-peptidic direct renin inhibitors for hypertension based on patents from 2000-2008.
Answers are grounded in this paper and cite their sources.
Patent trends may guide renin inhibitor design; leaves open clinical success beyond Phase II.
Background: The renin-angiotensin-aldosterone system (RAAS) is essential for the regulation of blood pressure and may play a critical role in the pathogenesis of cardiovascular diseases. A strong rationale suggests a more efficient control of RAAS by direct rather than downstream blockade of renin, an angiotensinogen-specific aspartic protease acting at the first, rate-limiting step of the pathway. Vast research efforts since the late 1970s have aimed at developing clinically useful renin inhibitors for the treatment of hypertension and associated co-morbidities. In 2007, aliskiren (Tekturna®, Rasilez®; Novartis) was launched as the first orally efficacious direct renin inhibitor. The evolution of non-peptide renin inhibitors interacting with non-substrate recognition sites of the enzyme, such as aliskiren and the 4-aryl-piperidines, during the 1990s encouraged an increasing number of pharmaceutical companies to resume, or newly embark on, drug discovery programs. Objective: This review summarizes the various structural design concepts and the apparent focus of activities presently employed to develop follow-up generations of oral renin inhibitors. Methods: Information was collected from patents, scientific literatures and public sources disclosed during the years 2000 – 2008. Results/conclusion: The structural diversity of small-molecule inhibitors has further increased, including novel basic surrogate transition-state mimetic motifs. Several inhibitors emerged as (pre)clinical candidates, the most advanced having entered Phase II clinical trials.
No takes yet. Share an insight, caveat, or question.
Yokokawa et al. (2008) conducted a review in Hypertension. Non-peptidic direct renin inhibitors was evaluated. Non-peptidic direct renin inhibitors have shown increasing structural diversity in patents from 2000-2008, with several novel small-molecule candidates advancing to Phase II clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: